About the Opportunity

About the Opportunity

Northeastern University Pharmaceutical Industry Fellowships Program is a two-year experiential program designed to advance lifelong learning and the education and training of Pharm.D. graduates. A key element of the program’s success is preparing Fellows to meet evolving workforce needs across various sectors of the pharmaceutical industry.

Fellows have the opportunity to work closely with our innovative biopharmaceutical industry partners, while engaging with Northeastern University faculty in professional and career development, teaching, service, and scholarly activities.

In partnership with Northeastern University, Alnylam Pharmaceuticals is offering a two-year Global Medical Affairs Early Assets fellowship, based in Cambridge, MA.

About Alnylam

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.

Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.

Responsibilities

Overview

The Medical Affairs organization at Alnylam plays a leading role in supporting pipeline assets, in preparing for launch, and supporting commercially available products, as we advance medicines for patients who have limited or inadequate treatment options. The Early Assets Medical Affairs function develops the medical strategy and leads medical execution to support the development of Alnylam’s investigational RNAi therapeutics. Early Assets Medical Affairs partners with experts across the organization to guide each unique investigational program as it enters the clinic and throughout its Ph 1 and Ph 2 development. Working cross-functionally across U.S. and global teams, key activities include mapping the clinical landscape, fostering scientific engagement with key opinion leaders (KOLs) and other stakeholders, and supporting the dissemination of early clinical study results. Fellows can also expect to contribute to strategic medical planning, champion congress engagements, support the development of medical materials, and collaborate with leaders from other key internal partners.

Key Responsibilities:

·       Lead therapeutic landscape and KOL mapping exercise to inform early program strategy, including supporting engagement planning and execution of advisory boards and medical congresses

·       Contribute to relationship building and insights generation with external stakeholders (KOLs, professional societies, and advocates)

·       Interpret pre-clinical and early clinical study results and develop publications support key messages for a clinical audience

·       Develop slide decks, posters, publications, and other materials to support clinical